Liquidia Co. (NASDAQ:LQDA) Receives $25.38 Average Target Price from Brokerages

Shares of Liquidia Co. (NASDAQ:LQDA) have received a consensus recommendation of “Buy” from the nine analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $25.38.

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Wells Fargo & Company assumed coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th.

Liquidia Stock Down 0.3 %

NASDAQ LQDA opened at $14.82 on Friday. The company has a market cap of $1.25 billion, a PE ratio of -9.09 and a beta of 0.07. Liquidia has a 52 week low of $8.26 and a 52 week high of $16.99. The firm’s 50-day simple moving average is $14.30 and its two-hundred day simple moving average is $11.86.

Insider Activity

In related news, insider Rajeev Saggar sold 2,445 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the transaction, the insider now directly owns 267,943 shares in the company, valued at approximately $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Kaseta sold 23,370 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the transaction, the chief financial officer now owns 401,755 shares in the company, valued at approximately $4,732,673.90. This trade represents a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,245 shares of company stock worth $843,326 over the last ninety days. Company insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC bought a new position in shares of Liquidia in the fourth quarter worth approximately $59,000. Summit Investment Advisors Inc. boosted its stake in Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after buying an additional 1,719 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Liquidia in the fourth quarter worth approximately $142,000. EntryPoint Capital LLC purchased a new stake in Liquidia in the fourth quarter worth approximately $154,000. Finally, Walleye Trading LLC boosted its stake in Liquidia by 54.7% in the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after buying an additional 4,670 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).